MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical ...

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE)-- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage ...

XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level ...

Thank you for joining us for INmune Bio's Fourth Quarter and Full Year 2025 Earnings Call. Today, I'll begin with an overview ...

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew ...

Image source: The Motley Fool. INmune Bio (NASDAQ:INMB) delivered an update signaling concrete progress across its CORDStrom and XPro platforms, as well as disciplined financial management. Regulatory ...

OmniScience and INmune Bio (INMB) announced a partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease, or AD, clinical trial using OmniScience’s product, Vivo, a ...

How Strong Is INmune Bio's Balance Sheet? We can see from the most recent balance sheet that INmune Bio had liabilities of US$3.23m falling due within a year, and liabilities of US$15.5m due beyond ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio, Inc. (NASDAQ:INMB) stands against ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Image source: The Motley Fool. INmune Bio (NASDAQ:INMB) highlighted its transition toward late-stage regulatory submissions, with CORDStrom's RDEB application preparations now in the advanced phase ...